HHV-6和HHV-7在异基因CAR-T细胞治疗中的再激活。

IF 14.9 1区工程技术 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Trends in biotechnology Pub Date : 2025-09-01 Epub Date: 2025-04-22 DOI:10.1016/j.tibtech.2025.03.017

Hiu Tung Chow, Wenjing Li, Bin Yang, Friedrich von Wintzingerode, Qi Chen

{"title":"HHV-6和HHV-7在异基因CAR-T细胞治疗中的再激活。","authors":"Hiu Tung Chow, Wenjing Li, Bin Yang, Friedrich von Wintzingerode, Qi Chen","doi":"10.1016/j.tibtech.2025.03.017","DOIUrl":null,"url":null,"abstract":"Autologous chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment and allogeneic CAR-T cell therapy is poised to advance this revolution. CAR-T cell therapy faces some concerns regarding adventitious agents, which can threaten the safety of patients. Human herpesviruses 6 and 7 (HHV-6 and HHV-7) have become increasingly notable in this context, as they carry a risk with severe health consequences. This review explores these virus reactivations in CAR-T cell therapy and discusses mitigation strategies during allogeneic CAR-T cell manufacturing. We provide an overview of prevention and testing strategies, genetic engineering applications, and chemical substances with potential for interventions. This review aims to enhance understanding of HHV reactivation and improve the safety of allogeneic CAR-T cell therapies.","PeriodicalId":23324,"journal":{"name":"Trends in biotechnology","volume":" ","pages":"2184-2196"},"PeriodicalIF":14.9000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"HHV-6 and HHV-7 reactivation in allogeneic CAR-T cell therapy.\",\"authors\":\"Hiu Tung Chow, Wenjing Li, Bin Yang, Friedrich von Wintzingerode, Qi Chen\",\"doi\":\"10.1016/j.tibtech.2025.03.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Autologous chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment and allogeneic CAR-T cell therapy is poised to advance this revolution. CAR-T cell therapy faces some concerns regarding adventitious agents, which can threaten the safety of patients. Human herpesviruses 6 and 7 (HHV-6 and HHV-7) have become increasingly notable in this context, as they carry a risk with severe health consequences. This review explores these virus reactivations in CAR-T cell therapy and discusses mitigation strategies during allogeneic CAR-T cell manufacturing. We provide an overview of prevention and testing strategies, genetic engineering applications, and chemical substances with potential for interventions. This review aims to enhance understanding of HHV reactivation and improve the safety of allogeneic CAR-T cell therapies.\",\"PeriodicalId\":23324,\"journal\":{\"name\":\"Trends in biotechnology\",\"volume\":\" \",\"pages\":\"2184-2196\"},\"PeriodicalIF\":14.9000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Trends in biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://doi.org/10.1016/j.tibtech.2025.03.017\",\"RegionNum\":1,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1016/j.tibtech.2025.03.017","RegionNum":1,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/22 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

自体嵌合抗原受体（CAR -T）细胞疗法已经彻底改变了癌症治疗，而同种异体CAR-T细胞疗法正准备推进这场革命。CAR-T细胞疗法面临着一些关于外来因素的担忧，这些因素可能威胁患者的安全。人类疱疹病毒6号和7号（HHV-6和HHV-7）在这方面变得越来越引人注目，因为它们具有严重健康后果的风险。这篇综述探讨了CAR-T细胞治疗中的这些病毒再激活，并讨论了同种异体CAR-T细胞制造过程中的缓解策略。我们提供了预防和测试策略的概述，基因工程的应用，和化学物质与潜在的干预。本综述旨在加强对HHV再激活的认识，提高同种异体CAR-T细胞治疗的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

HHV-6 and HHV-7 reactivation in allogeneic CAR-T cell therapy.

Autologous chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment and allogeneic CAR-T cell therapy is poised to advance this revolution. CAR-T cell therapy faces some concerns regarding adventitious agents, which can threaten the safety of patients. Human herpesviruses 6 and 7 (HHV-6 and HHV-7) have become increasingly notable in this context, as they carry a risk with severe health consequences. This review explores these virus reactivations in CAR-T cell therapy and discusses mitigation strategies during allogeneic CAR-T cell manufacturing. We provide an overview of prevention and testing strategies, genetic engineering applications, and chemical substances with potential for interventions. This review aims to enhance understanding of HHV reactivation and improve the safety of allogeneic CAR-T cell therapies.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in biotechnology 工程技术-生物工程与应用微生物

CiteScore

28.60

自引率

1.20%

发文量

198

审稿时长

1 months

期刊介绍： Trends in Biotechnology publishes reviews and perspectives on the applied biological sciences, focusing on useful science applied to, derived from, or inspired by living systems. The major themes that TIBTECH is interested in include: Bioprocessing (biochemical engineering, applied enzymology, industrial biotechnology, biofuels, metabolic engineering) Omics (genome editing, single-cell technologies, bioinformatics, synthetic biology) Materials and devices (bionanotechnology, biomaterials, diagnostics/imaging/detection, soft robotics, biosensors/bioelectronics) Therapeutics (biofabrication, stem cells, tissue engineering and regenerative medicine, antibodies and other protein drugs, drug delivery) Agroenvironment (environmental engineering, bioremediation, genetically modified crops, sustainable development).